HBM Holdings reports profit and revenue surge driven by strategic collaborations

HBM Holdings Limited reported a profit of $73.0m for the six months ended 30 June 2025, a substantial increase from $1.4m in the same period of 2024. Revenue surged to $101.3m, up 327.5% from $23.7m year-over-year. Molecule license revenue was a primary contributor, rising from $20.8m to $93.7m.

The company's basic and diluted earnings per share both reached $0.09 for the period, compared to $0.00 in the prior year. Cash and cash equivalents more than doubled to $320.7m as of 30 June 2025, from $166.8m at the end of 2024. Total assets also increased to $380.5m, up from $215.0m.

Key business developments included a global strategic collaboration with AstraZeneca, potentially valued at $4.6bn in upfront and milestone payments, and an equity investment of $105m. HBM Holdings also entered into an exclusive license agreement with Windward Bio for HBM9378/WIN378, with potential payments up to $970m.